136 related articles for article (PubMed ID: 16331792)
1. Synovial tissue analysis in clinical trials.
Bresnihan B; Baeten D; Firestein GS; Fitzgerald OM; Gerlag DM; Haringman JJ; McInnes IB; Reece RJ; Smith MD; Ulfgren AK; Veale DJ; Tak PP;
J Rheumatol; 2005 Dec; 32(12):2481-4. PubMed ID: 16331792
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.
Humby F; Kelly S; Bugatti S; Manzo A; Filer A; Mahto A; Fonseca JE; Lauwerys B; D'Agostino MA; Naredo E; Lories R; Montecucco C; Tak PP; Fitzgerald O; Smith MD; Veale DJ; Choy EH; Strand V; Pitzalis C
J Rheumatol; 2016 Jan; 43(1):208-13. PubMed ID: 26034155
[TBL] [Abstract][Full Text] [Related]
3. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials.
van de Sande MG; Gerlag DM; Lodde BM; van Baarsen LG; Alivernini S; Codullo V; Felea I; Vieira-Sousa E; Fearon U; Reece R; Montecucco C; Veale DJ; Pitzalis C; Emery P; Klareskog L; McInnes IB; Tak PP
Ann Rheum Dis; 2011 Mar; 70(3):423-7. PubMed ID: 21109518
[TBL] [Abstract][Full Text] [Related]
4. Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?
Tak PP
J Rheumatol Suppl; 2005 Jan; 72():25-6. PubMed ID: 15660460
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment.
Smith MD; Weedon H; Papangelis V; Walker J; Roberts-Thomson PJ; Ahern MJ
Rheumatology (Oxford); 2010 May; 49(5):862-75. PubMed ID: 20147446
[TBL] [Abstract][Full Text] [Related]
6. The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis.
Wechalekar MD; Najm A; Veale DJ; Strand V
J Rheumatol; 2019 Oct; 46(10):1365-1368. PubMed ID: 30647173
[TBL] [Abstract][Full Text] [Related]
7. Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
Furst DE
Lancet; 2000 Jul; 356(9225):183-4. PubMed ID: 10963194
[No Abstract] [Full Text] [Related]
8. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Zwinderman AH; Smeets TJ; Kraan MC; Baeten D; McInnes IB; Bresnihan B; Tak PP
Ann Rheum Dis; 2005 Jun; 64(6):834-8. PubMed ID: 15576415
[TBL] [Abstract][Full Text] [Related]
9. The needle and the damage done.
Franz JK; Burmester GR
Ann Rheum Dis; 2005 Jun; 64(6):798-800. PubMed ID: 15897300
[No Abstract] [Full Text] [Related]
10. Therapeutic effect of cytembena in rheumatoid arthritis.
Truhlár P; Machácek P; Smahel O
Int J Clin Pharmacol; 1973 Nov; 8(3):189-93. PubMed ID: 4589327
[No Abstract] [Full Text] [Related]
11. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
Lisbona MP; Maymo J; Perich J; Almirall M; Pérez-García C; Carbonell J
J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
[TBL] [Abstract][Full Text] [Related]
12. New learnings on the pathophysiology of RA from synovial biopsies.
Pitzalis C; Kelly S; Humby F
Curr Opin Rheumatol; 2013 May; 25(3):334-44. PubMed ID: 23492740
[TBL] [Abstract][Full Text] [Related]
13. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
14. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying antirheumatic drugs.
Pincus T; Breedveld FC; Emery P
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S2-7. PubMed ID: 10589350
[No Abstract] [Full Text] [Related]
15. Rheumatoid arthritis: inflammation and bone loss.
Schett G
Wien Med Wochenschr; 2006 Jan; 156(1-2):34-41. PubMed ID: 16465612
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
van Holten J; Pavelka K; Vencovsky J; Stahl H; Rozman B; Genovese M; Kivitz AJ; Alvaro J; Nuki G; Furst DE; Herrero-Beaumont G; McInnes IB; Musikic P; Tak PP
Ann Rheum Dis; 2005 Jan; 64(1):64-9. PubMed ID: 15242865
[TBL] [Abstract][Full Text] [Related]
17. Key randomized trials of single agents in early rheumatoid arthritis.
van de Putte LB
J Rheumatol Suppl; 2002 Nov; 66():13-9. PubMed ID: 12435164
[TBL] [Abstract][Full Text] [Related]
18. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis.
Haringman JJ; Vinkenoog M; Gerlag DM; Smeets TJ; Zwinderman AH; Tak PP
Arthritis Res Ther; 2005; 7(4):R862-7. PubMed ID: 15987488
[TBL] [Abstract][Full Text] [Related]
19. Remission in early rheumatoid arthritis.
Ma MH; Scott IC; Kingsley GH; Scott DL
J Rheumatol; 2010 Jul; 37(7):1444-53. PubMed ID: 20516031
[TBL] [Abstract][Full Text] [Related]
20. Current immunotherapy in rheumatoid arthritis.
Meier FM; Frerix M; Hermann W; Müller-Ladner U
Immunotherapy; 2013 Sep; 5(9):955-74. PubMed ID: 23998731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
